Skip to main content

What Viatris's Quarter ended Sep 30, 2026 10-Q says: 5 signals

Viatris filed its latest 10-Q with the SEC on Nov 5, 2026. It discusses acquisition announced, cost reduction and divestiture.

Public (VTRS)Pharmaceutical Manufacturing10,000+ employeesviatris.comLinkedIn

Get Viatris' live signals in Claude or ChatGPT, or by API

AskWhat changed at Viatris this week? Use Autobound signals for viatris.com.
Filed
Nov 5, 2026
Period
Quarter ended Sep 30, 2026
Filings
3
Signals
16

Source: Autobound Signal API · 76 signals tracked for Viatris · updated

10-Q · latest 10

What Viatris's 10-Q filings say

  1. 10-Q · Quarter ended Sep 30, 2026

    Filed · 5 signals

    SEC EDGAR
  2. 10-Q · Quarter ended Jun 30, 2026

    Filed · 5 signals

    SEC EDGAR

Earlier 10-Q filings

  • 10-Q · Quarter ended Mar 31, 2026Filed · 6 signalsSEC EDGAR

Showing 10 of 16 filing signals. The Signal API returns all of them.

Get them with one API call

Earnings calls

Viatris earnings headlines

From earnings call transcripts (Signal API type earnings-transcripts).

Earnings call headlines
Call dateWhat the company said
Q3 revenue of $3.75B with 2% nine-month operational growthDelivered total Q3 revenues of $3.75B and adjusted EBITDA of $1.2B with a 58% adjusted gross margin. Through the first 9 months of 2026, total revenues grew 2%, adjusted EBITDA grew 6%, and adjusted EPS grew 8% operationally. Strong performance in Greater China and North America offset supply constraints affecting lower-margin generics in Europe and emerging markets.
Agreement to acquire Pacira BioSciences closing in November 2026Launched a tender offer on October 30 to acquire Pacira BioSciences, scheduled to close before the end of November 2026 funded by excess cash and credit lines. The transaction adds patent-protected medicines EXPAREL and ZILRETTA, supporting an expected $1B+ in 2027 U.S. innovative medicine revenue and over $50M in annual cost synergies by 2028. The deal also expands commercial sales, medical...
Full year 2026 financial guidance raised across all key metricsManagement narrowed guidance ranges and raised midpoints for full year 2026 financial metrics based on year-to-date performance. Revised midpoint expectations call for operational growth of 2% in revenue, 6% in adjusted EBITDA, and 8% in adjusted EPS, excluding Pacira contributions. This outlook balances Q4 supply disruptions of $100M in Europe and emerging markets against accelerating North...
North America net sales up 7% driven by complex genericsQ3 North America net sales grew 7% year-over-year, driven by high-margin complex generics and doubled volumes of estradiol patch products. Complex generics and estradiol patches accounted for over 65% of North American generics net sales during the quarter. Full-year 2026 regional guidance was revised upward from flat to high single-digit growth.
Commercial launch of Gwyn Lo patch and multiple approvalsLaunched Gwyn Lo low-dose contraceptive patch in the U.S. in October 2026 and preparing for once-monthly aripiprazole injection launch. Also secured U.S. FDA approval for Ryzumvi for presbyopia and Japanese regulatory approval for Wakix. The company is tracking more than 100 new product approvals in 2026 and preparing for a potential early 2027 U.S. launch of fast-acting meloxicam pending a...
Nashik facility suspension causes $100M quarterly revenue impactViatris suspended manufacturing at its Nashik facility following FDA 483 observations and an Official Action Indicated (OAI) classification. The resulting supply constraints reduced Q3 revenue by approximately $100 million and are projected to cause another $100 million headwind in Q4 across Europe and emerging markets. This disruption creates opportunities for supply chain remediation...

Signal API · MCP

Track Viatris with the Signal API

One POST /v1/companies/enrich call with viatris.com returns Viatris 10-Q signals (sec-10q), each with its source. Or ask Claude through MCP.

2 credits per signal returned; zero-result calls are free. Endpoint reference

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"viatris.com","signal_types":["sec-10q"],"limit":20}'

Bulk data

Need this signal for 10,000+ companies?

Get a free sample file or a bulk feed (API, GCS push, flat file). The sample is real 10-Q Filings records, as a CSV.

Talk to sales

Same industry

Questions about Viatris 10-Q

When did Viatris file its latest 10-Q?
Viatris filed its latest 10-Q (Quarter ended Sep 30, 2026) on Nov 5, 2026. The one before it was filed on Aug 6, 2026.
What did Viatris disclose in its latest 10-Q?
From the filing dated Nov 5, 2026: Viatris to acquire Pacira for $36.50 per share in cash, totaling $1.65 billion
What did Viatris say on its recent earnings calls?
Q3 FY2026: Q3 revenue of $3.75B with 2% nine-month operational growth (dated Nov 5, 2026).
Where can I read Viatris's 10-Q filing?
The full filing is on SEC EDGAR: https://www.sec.gov/Archives/edgar/data/1792044/000179204426000057/vtrs-20260930.htm. This page summarizes what the filing says and links to it.

Page updated , the date of the newest row on this page.

Source. Quarterly reports (Form 10-Q) filed with the SEC. Every card links to the filing on EDGAR.

Method. Insights are extracted from the filing text and grouped by category. Numbers are quoted from the filing.

Data as of .

How this data is built →Get it from the Signal API →